- Home
- CET vs GHRS Comparison
CET vs GHRS Comparison
Compare CET & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CET | GHRS |
|---|---|---|
| Founded | 1929 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CET | GHRS |
|---|---|---|
| Price | $52.37 | $28.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $41.38 |
| AVG Volume (30 Days) | 40.2K | ★ 233.7K |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | ★ 5.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $47.76 | $11.32 |
| 52 Week High | $54.65 | $31.00 |
Technical Indicators
Market Signals| Indicator | CET | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 46.81 | 65.84 |
| Support Level | $52.23 | $12.88 |
| Resistance Level | $52.52 | $28.96 |
| Average True Range (ATR) | 0.64 | 1.66 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 40.00 | 65.92 |
Price Performance
Historical ComparisonAbout CET Central Securities Corporation
Central Securities Corp is a non-diversified closed-end management investment company. The company's investment objective is long-term growth of capital. It invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.